Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate

Melissa J. Chen, Mitchell D. Creinin, David K. Turok, David F. Archer, Kurt T. Barnhart, Carolyn L. Westhoff, Michael A. Thomas, Jeffrey T. Jensen, Bruce Variano, Regine Sitruk-Ware, Anita Shanker, Jill Long, Diana L. Blithe

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate serum estradiol (E2) concentrations during use of 90-day contraceptive vaginal rings releasing E2 75, 100, or 200 mcg/day and segesterone acetate (SA) 200 mcg/day to identify a dose that avoids hypoestrogenism. Study design: We conducted a multicenter dose-finding study in healthy, reproductive-aged women with regular cycles with sequential enrollment to increasing E2 dose groups. We evaluated serum E2 concentrations twice weekly for the primary outcome of median E2 concentrations throughout initial 30-day use (target ≥40 pg/mL). In an optional 2-cycle extension substudy, we randomized participants to 2- or 4-day ring-free intervals per 30-day cycle to evaluate bleeding and spotting based on daily diary information. Results: Sixty-five participants enrolled in E2 75 (n = 22), 100 (n = 21), and 200 (n = 22) mcg/day groups; 35 participated in the substudy. Median serum E2 concentrations in 75 and 100 mcg/day groups were <40 pg/mL. In the 200 mcg/day group, median E2 concentrations peaked on days 4–5 of CVR use at 194 pg/mL (range 114–312 pg/mL) and remained >40 pg/mL throughout 30 days; E2 concentrations were 37 pg/mL (range 28–62 pg/mL) on days 88–90 (n = 11). Among the E2 200 mcg/day substudy participants, all had withdrawal bleeding following ring removal. The 2-day ring-free interval group reported zero median unscheduled bleeding and two (range 0–16) and three (range 0–19) unscheduled spotting days in extension cycles 1 and 2, respectively. The 4-day ring-free interval group reported zero median unscheduled bleeding or spotting days. Conclusions: Estradiol concentrations with rings releasing E2 200 mcg/day and SA 200 mcg/day avoid hypoestrogenism over 30-day use. Implications: A 90-day contraceptive vaginal ring releasing estradiol 200 mcg/day and segesterone acetate 200 mcg/day achieves estradiol concentrations that should avoid hypoestrogenism and effectively suppresses ovulation.

Original languageEnglish (US)
Pages (from-to)168-173
Number of pages6
JournalContraception
Volume102
Issue number3
DOIs
StatePublished - Sep 2020

Keywords

  • Clinical trial
  • Contraception
  • Estradiol
  • Nestorone®
  • Segesterone acetate
  • Vaginal ring

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate'. Together they form a unique fingerprint.

  • Cite this

    Chen, M. J., Creinin, M. D., Turok, D. K., Archer, D. F., Barnhart, K. T., Westhoff, C. L., Thomas, M. A., Jensen, J. T., Variano, B., Sitruk-Ware, R., Shanker, A., Long, J., & Blithe, D. L. (2020). Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. Contraception, 102(3), 168-173. https://doi.org/10.1016/j.contraception.2020.05.004